Randomization and blinding
Participants within each patient group (CP-A/-B) were randomized 3:1 to receive oral tablets of BI 685509 (1 of 3 dose groups; maximum tested doses after dose escalation: 1 mg twice daily [BID], 2 mg BID, 3 mg BID) or placebo (Supplemental Table S1, 